Manish Chamoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Manish Chamoli has a total of 327 co-authors. Here are the top co-authors by number of shared publications:
- Quynh-Thu Le
Stanford University School of Medicine, Stanford, CA, USA
27 shared publications - Vignesh Viswanathan
Manning College of Information and Computer Sciences, University of Massachusetts Amherst
26 shared publications - Amanda Jeanette. Koong
Affiliation McGovern School of Medicine, Houston, Texas, USA and UCLA, Fielding School of Public Health, Los Angeles, California, United States of America
25 shared publications - Amato J. Giaccia
Department of Oncology, University of Oxford, Oxford, UK
25 shared publications - Brittany J. Holmes
Department of Pathology, Stanford University, Stanford, California
25 shared publications - Christina S. Kong
Department of Pathology, Stanford University School of Medicine, Stanford, USA
25 shared publications
Latest Publications
- Open Access
Shifts in protein aggregate stability define proteostasis decline in the aging human brain
Loss of proteostasis and the accumulation of insoluble protein aggregates are features of aging across model organisms and occur in all major age-related neurodegenerative diseases; yet how aggregation proceeds during normal human brain aging remains unknown. Using detergent-fractionation proteomics, we show that human brain aging does not involve uniform aggregate accumulation; rather, the insoluble proteome undergoes asymmetric remodeling beginning in midlife. Maximum-stability aggregates decline sharply in old age whereas intermediate-stability aggregates accumulate gradually before accelerating after age 80. Intermediate-stability aggregates are prone to liquid-liquid phase separation and are enriched with Alzheimer’s disease plaque and tangle constituents. Proteasome and cytosolic chaperone abundance predict individual differences in aggregate burden as strongly as age, offering supportive evidence, in humans, for therapies targeting these pathways. These findings establish aggregate remodeling as a feature of normal brain aging and position the accumulation of intermediate-stability aggregates as a molecular event on the path to neurodegenerative disease.
Open AccessShifts in protein aggregate stability define proteostasis decline in the aging human brain
Loss of proteostasis and the accumulation of insoluble protein aggregates are features of aging across model organisms and occur in all major age-related neurodegenerative diseases; yet how aggregation proceeds during normal human brain aging remains unknown. Using detergent-fractionation proteomics, we show that human brain aging does not involve uniform aggregate accumulation; rather, the insoluble proteome undergoes asymmetric remodeling beginning in midlife. Maximum-stability aggregates decline sharply in old age whereas intermediate-stability aggregates accumulate gradually before accelerating after age 80. Intermediate-stability aggregates are prone to liquid-liquid phase separation and are enriched with Alzheimer’s disease plaque and tangle constituents. Proteasome and cytosolic chaperone abundance predict individual differences in aggregate burden as strongly as age, offering supportive evidence, in humans, for therapies targeting these pathways. These findings establish aggregate remodeling as a feature of normal brain aging and position the accumulation of intermediate-stability aggregates as a molecular event on the path to neurodegenerative disease.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Sh-RNA knockdown sequences used in the study
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Sh-RNA knockdown sequences used in the study
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Terminal Tumor volume of MOC2 WT/KO-Gal1 tumors in Rag2-/- IL2rg-/- mice. B. Gating strategy used for analyses of PMN-MDSCs and M-MDSCs in tumor and lung tissues. C. Unsupervised tSNE clustering of live cells in MOC2 WT/KO-Gal1 tumor showing the proportion of M-MDSC, PMN-MDSC, and CD8+ T cells. D. Visual representation of the spleens isolated from either naïve mice or mice bearing WT- or KO-Gal1 tumors. E. Comparison of MDSC enrichment scores between smaller T1-2 and larger T3-4 tumors in the HNSCC TCGA cohort. The student’s t-test was used to assess the significance of the difference between the two groups. F. Heat map showing gene expression clustering based on the MDSC enrichment score in the HNSCC TCGA cohort. Differentially expressed genes (DEGs) were defined by a false discovery rate smaller than 0.05 and fold change higher than 1.5. G. Representative images showing low and high staining Gal1 or LOX1 (OLR1, established marker of PMN-MDSCs) using immunohistochemistry (IHC). H. Table showing the distribution of tumors expressing high or low Gal1 and high or low LOX1 (PMN-MDSCs) in 81 patients with oral cavity tumors. Gal1 and LOX1 staining distribution was analyzed using a chi-square test and was not statistically significant.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Terminal Tumor volume of MOC2 WT/KO-Gal1 tumors in Rag2-/- IL2rg-/- mice. B. Gating strategy used for analyses of PMN-MDSCs and M-MDSCs in tumor and lung tissues. C. Unsupervised tSNE clustering of live cells in MOC2 WT/KO-Gal1 tumor showing the proportion of M-MDSC, PMN-MDSC, and CD8+ T cells. D. Visual representation of the spleens isolated from either naïve mice or mice bearing WT- or KO-Gal1 tumors. E. Comparison of MDSC enrichment scores between smaller T1-2 and larger T3-4 tumors in the HNSCC TCGA cohort. The student’s t-test was used to assess the significance of the difference between the two groups. F. Heat map showing gene expression clustering based on the MDSC enrichment score in the HNSCC TCGA cohort. Differentially expressed genes (DEGs) were defined by a false discovery rate smaller than 0.05 and fold change higher than 1.5. G. Representative images showing low and high staining Gal1 or LOX1 (OLR1, established marker of PMN-MDSCs) using immunohistochemistry (IHC). H. Table showing the distribution of tumors expressing high or low Gal1 and high or low LOX1 (PMN-MDSCs) in 81 patients with oral cavity tumors. Gal1 and LOX1 staining distribution was analyzed using a chi-square test and was not statistically significant.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Immunoblot showing knockdown of STING in MOC2 WT/KO cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Immunoblot showing knockdown of STING in MOC2 WT/KO cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Quantification of PMN-MDSCs (CD11b+Ly6Clo/intLy6G+) in the liver and kidneys of MOC2 WT- or KO-Gal1 tumor-bearing mice at matched tumor volumes in comparison with naïve mice. B. Gating strategy used to quantify Arginase (Arg1) and interleukin-10 (IL-10) expression on PMN-MDSCs isolated from the tumor or the lungs of naïve mice or mice with pre-metastatic niches (sub-gated on CD45+ live cells). C. Heat map showing differential gene expression from PMN-MDSCs isolated from tumor and lung tissues of MOC2 WT-Gal1 tumor-bearing mice compared with naïve neutrophils. D. STRING analysis showing two clusters of genes representing IL-17 and collagen synthesis pathways that are upregulated PMN-MDSCs isolated from pre-metastatic lung tissues. E. Reactome pathway enrichment analyses performed using RNA-SEQ data showing pathway represented by upregulated genes in PMN-MDSCs isolated from pre-metastatic lung tissues. F. Quantification of Trichrome staining intensity in mEERL WT- or KO-Gal1 tumor-bearing mice lungs, n=5/group. G. tSNE plot showing depletion of PMN-MDSCs in the blood following injection of anti-GR1 antibody in mice compared with isotype alone.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Quantification of PMN-MDSCs (CD11b+Ly6Clo/intLy6G+) in the liver and kidneys of MOC2 WT- or KO-Gal1 tumor-bearing mice at matched tumor volumes in comparison with naïve mice. B. Gating strategy used to quantify Arginase (Arg1) and interleukin-10 (IL-10) expression on PMN-MDSCs isolated from the tumor or the lungs of naïve mice or mice with pre-metastatic niches (sub-gated on CD45+ live cells). C. Heat map showing differential gene expression from PMN-MDSCs isolated from tumor and lung tissues of MOC2 WT-Gal1 tumor-bearing mice compared with naïve neutrophils. D. STRING analysis showing two clusters of genes representing IL-17 and collagen synthesis pathways that are upregulated PMN-MDSCs isolated from pre-metastatic lung tissues. E. Reactome pathway enrichment analyses performed using RNA-SEQ data showing pathway represented by upregulated genes in PMN-MDSCs isolated from pre-metastatic lung tissues. F. Quantification of Trichrome staining intensity in mEERL WT- or KO-Gal1 tumor-bearing mice lungs, n=5/group. G. tSNE plot showing depletion of PMN-MDSCs in the blood following injection of anti-GR1 antibody in mice compared with isotype alone.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Gating strategy for CD8+ T cells in the spleen of mice treated with either MOC2 WT/KO-Gal1 CM. B. Quantitation of PMN-MDSCs and T cells in the spleen of mice bearing KO-Gal1 tumors injected with either WT- or KO-Gal1 CM for 3 weeks. C. Graph showing the 48-plex mouse cytokine Luminex assay results performed on the 10x concentrated condition media from MOC2 WT/KO-Gal1 tumor cells. The media was collected in 3 independent experiments and run as a single batch. D. Gating strategy for CXCR2 staining on PMN-MDSCs isolated from the tumor and pre-metastatic lungs.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Gating strategy for CD8+ T cells in the spleen of mice treated with either MOC2 WT/KO-Gal1 CM. B. Quantitation of PMN-MDSCs and T cells in the spleen of mice bearing KO-Gal1 tumors injected with either WT- or KO-Gal1 CM for 3 weeks. C. Graph showing the 48-plex mouse cytokine Luminex assay results performed on the 10x concentrated condition media from MOC2 WT/KO-Gal1 tumor cells. The media was collected in 3 independent experiments and run as a single batch. D. Gating strategy for CXCR2 staining on PMN-MDSCs isolated from the tumor and pre-metastatic lungs.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Quantification of phospho-p65 (NF-kb) staining in MOC2 and mEERL WT/KO-Gal1 tumors (N=5 tumors, 3 random microscopic fields per tumor). B. Quantitation of STING mRNA levels in MOC2 and mEERL WT/KO-Gal1 cell lines. C. Immunoblot showing degradation kinetics of STING in LLC and FaDU WT/KD-Gal1 cells at 1, 2, 4h post cycloheximide treatment. D. Magnified images showing co-localization of STING and LAMP1 in MOC2 WT/KO-Gal1 cells. E. Representative images showing low and high IHC staining of STING in oral cavity cancer (Left) and the distribution of negative and positive STING staining in 83 oral cavity cancers on the TMA. F. Kaplan Meier curve showing progression-free survival (calculated as the time from the surgery date until death or progression) of patients based on Gal1 and STING expression in the tumor.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Quantification of phospho-p65 (NF-kb) staining in MOC2 and mEERL WT/KO-Gal1 tumors (N=5 tumors, 3 random microscopic fields per tumor). B. Quantitation of STING mRNA levels in MOC2 and mEERL WT/KO-Gal1 cell lines. C. Immunoblot showing degradation kinetics of STING in LLC and FaDU WT/KD-Gal1 cells at 1, 2, 4h post cycloheximide treatment. D. Magnified images showing co-localization of STING and LAMP1 in MOC2 WT/KO-Gal1 cells. E. Representative images showing low and high IHC staining of STING in oral cavity cancer (Left) and the distribution of negative and positive STING staining in 83 oral cavity cancers on the TMA. F. Kaplan Meier curve showing progression-free survival (calculated as the time from the surgery date until death or progression) of patients based on Gal1 and STING expression in the tumor.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Representative gating strategy for quantification of PMN-MDSCs, M-MDSCs, Ly6C+Mo-MØs, Alveolar macrophages (AMs), Interstitial macrophages (IMs) and myeloid DCs in the lungs of tumor-bearing mice. B. Quantification of PMN-MDSCs (CD11b+Ly6Clo/intLy6G+) in the lungs of MOC2 WT- or KO-Gal1 tumor-bearing mice at matched tumor volumes and of naïve mice. C. Quantitation of CD4+ and CD8+ T cells in MOC2 WT/KO-Gal1 tumor-bearing mice lungs at matched tumor volumes. D. Quantitation of CD8+ T cells in the blood after treatment with either isotype control IgG or anti-mouse CD8a antibody (clone 2.43, BioXCell, 400 μg i.p. twice weekly) in mice bearing MOC2 WT- or KO-Gal1 tumors. E. Quantitation of PMN-MDSCs in the lungs after treatment with either isotype control IgG or anti-mouse CD8a antibody i.p. twice weekly in mice bearing MOC2 WT- or KO-Gal1 tumors. Each dot represents one mouse, and the bar denotes the mean. Student’s t-test (two-tailed) was used to compare the two groups. One-way ANOVA with Tukey’s adjustment was used for comparing multiple treatments to each other. Data are shown as mean+/-SD.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Representative gating strategy for quantification of PMN-MDSCs, M-MDSCs, Ly6C+Mo-MØs, Alveolar macrophages (AMs), Interstitial macrophages (IMs) and myeloid DCs in the lungs of tumor-bearing mice. B. Quantification of PMN-MDSCs (CD11b+Ly6Clo/intLy6G+) in the lungs of MOC2 WT- or KO-Gal1 tumor-bearing mice at matched tumor volumes and of naïve mice. C. Quantitation of CD4+ and CD8+ T cells in MOC2 WT/KO-Gal1 tumor-bearing mice lungs at matched tumor volumes. D. Quantitation of CD8+ T cells in the blood after treatment with either isotype control IgG or anti-mouse CD8a antibody (clone 2.43, BioXCell, 400 μg i.p. twice weekly) in mice bearing MOC2 WT- or KO-Gal1 tumors. E. Quantitation of PMN-MDSCs in the lungs after treatment with either isotype control IgG or anti-mouse CD8a antibody i.p. twice weekly in mice bearing MOC2 WT- or KO-Gal1 tumors. Each dot represents one mouse, and the bar denotes the mean. Student’s t-test (two-tailed) was used to compare the two groups. One-way ANOVA with Tukey’s adjustment was used for comparing multiple treatments to each other. Data are shown as mean+/-SD.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
The immune system plays a crucial role in the regulation of metastasis. Tumor cells systemically change immune functions to facilitate metastatic progression. Through this study, we deciphered how tumoral galectin-1 (Gal1) expression shapes the systemic immune environment to promote metastasis in head and neck cancer (HNC). In multiple preclinical models of HNC and lung cancer in immunogenic mice, Gal1 fostered the establishment of a premetastatic niche through polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC), which altered the local microenvironment to support metastatic spread. RNA sequencing of MDSCs from premetastatic lungs in these models demonstrated the role of PMN-MDSCs in collagen and extracellular matrix remodeling in the premetastatic compartment. Gal1 promoted MDSC accumulation in the premetastatic niche through the NF-κB signaling axis, triggering enhanced CXCL2-mediated MDSC migration. Mechanistically, Gal1 sustained NF-κB activation in tumor cells by enhancing stimulator of interferon gene (STING) protein stability, leading to prolonged inflammation-driven MDSC expansion. These findings suggest an unexpected protumoral role of STING activation in metastatic progression and establish Gal1 as an endogenous-positive regulator of STING in advanced-stage cancers.Significance:Galectin-1 increases STING stability in cancer cells that activates NF-κB signaling and CXCL2 expression to promote MDSC trafficking, which stimulates the generation of a premetastatic niche and facilitates metastatic progression.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
The immune system plays a crucial role in the regulation of metastasis. Tumor cells systemically change immune functions to facilitate metastatic progression. Through this study, we deciphered how tumoral galectin-1 (Gal1) expression shapes the systemic immune environment to promote metastasis in head and neck cancer (HNC). In multiple preclinical models of HNC and lung cancer in immunogenic mice, Gal1 fostered the establishment of a premetastatic niche through polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC), which altered the local microenvironment to support metastatic spread. RNA sequencing of MDSCs from premetastatic lungs in these models demonstrated the role of PMN-MDSCs in collagen and extracellular matrix remodeling in the premetastatic compartment. Gal1 promoted MDSC accumulation in the premetastatic niche through the NF-κB signaling axis, triggering enhanced CXCL2-mediated MDSC migration. Mechanistically, Gal1 sustained NF-κB activation in tumor cells by enhancing stimulator of interferon gene (STING) protein stability, leading to prolonged inflammation-driven MDSC expansion. These findings suggest an unexpected protumoral role of STING activation in metastatic progression and establish Gal1 as an endogenous-positive regulator of STING in advanced-stage cancers.Significance:Galectin-1 increases STING stability in cancer cells that activates NF-κB signaling and CXCL2 expression to promote MDSC trafficking, which stimulates the generation of a premetastatic niche and facilitates metastatic progression.
- 1 April 2025
- Published by Springer Nature in Journal of Biosciences
- Vol. 50 (2) , 1-13
Kinome-wide RNAi screening in Caenorhabditis elegans reveals new modulators of insulin signaling and longevity
- 1 April 2025
- Published by Springer Nature in Journal of Biosciences
- Vol. 50 (2) , 1-13
Kinome-wide RNAi screening in Caenorhabditis elegans reveals new modulators of insulin signaling and longevity